Zhengye Biotechnology Holding Limited (ZYBT)

Every figure this model derived for ZYBT, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 144,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 7,420,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2025-12-31
current assets 19,650,000 AssetsCurrent 2025-12-31
current liabilities 17,230,000 LiabilitiesCurrent 2025-12-31
equity 35,722,000 StockholdersEquity 2025-12-31
interest expense 486,000 InterestExpenseDebt 2025-12-31
ocf 1,911,000 NetCashProvidedByUsedInOperatingActivities 2025-12-31
revenue 16,639,000 Revenues 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up ZYBT on one particular measure came for.

RatioValue
cash operating margin-38.36
current ratio1.19
current ratio reported1.14
deferred revenue growth42.56
dilution pct3.69
fcf margin10.62
interest cover-20.75
operating margin-60.6
owner earnings margin10.62
revenue growth-34.83
revenue growth per share-37.15
roic-26.76
rule of 40-95.43
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about ZYBT's figures. Written by the derivation as it ran, not added afterwards.